

Special Issue

Cancer Vaccines and Immunotherapies

Message from the Guest Editor

This Special Issue aims to highlight cutting-edge research in the rapidly evolving field of cancer vaccines and immunotherapy, with a particular focus on novel vaccine strategies and immune-based treatments. We welcome original research, review articles, and perspective manuscripts that explore advancements in cancer vaccine development, immune modulation, and novel therapeutic approaches. Topics of interest include, but are not limited to, **mRNA cancer vaccines, combination immunotherapies (checkpoint inhibitors, cytokine therapies, and immune adjuvants), dendritic cell-based vaccines, tumor-derived exosome vaccines, and neoantigen-based personalized cancer vaccines**. Additionally, we encourage submissions related to tumor microenvironment modulation for vaccine efficacy, CAR-T and TCR-T cell therapies, novel adjuvants and delivery systems, and biomarker-driven predictive models for vaccine response. Emerging areas such as **AI-driven vaccine design, multi-omics approaches in tumor immunology, microbiome interactions with cancer immunotherapy, and epigenetic modulation of immune responses** are also highly relevant to this Special Issue.

Guest Editor

Prof. Dr. Subbaya Subramanian

Department of Surgery, University of Minnesota, Minneapolis, MN 55455, USA

Deadline for manuscript submissions

31 March 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/237555

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).